Overview
In plain English
GLOW is three peptides in one vial: GHK-Cu 50mg, TB-500 10mg and BPC-157 10mg.
It combines three separately characterised repair mechanisms — copper delivery to matrix enzymes from GHK-Cu, actin-mediated cell migration from TB-500 and angiogenic signalling from BPC-157 — in one lyophilised vial at a fixed ratio. Strictly for laboratory research use. Not for human or veterinary consumption.
- What it isThree peptides in one vial: GHK-Cu, TB-500, BPC-157 (70mg total)
- Mainly studied forMatrix maturation, cell migration and vascular supply in tissue-repair models
- Supplied asLyophilised powder, single 70mg vial at a fixed ratio, independently assayed
How it works
What it actually does
GHK-Cu carries copper to lysyl oxidase, the enzyme that cross-links collagen and elastin. Without that step new collagen never matures into load-bearing fibre.
TB-500 regulates the actin scaffolding repair cells use to move into damaged tissue.
BPC-157 is associated with new blood vessel growth into that tissue. Three separate jobs, no shared pathway — which is the reason for combining them.
The science in detail
GLOW places three separately characterised peptides in one vial. Their mechanisms do not intersect, and the rationale for combining them is that separation rather than any shared pathway.
GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine complexed with copper(II). Its defining chemistry is copper coordination: the N-terminal amine, the deprotonated amide nitrogen of the first peptide bond and the histidine imidazole form a square-planar chelation site with affinity comparable to serum albumin. GHK does not sequester copper inertly — it accepts Cu2+ from albumin and passes it to cellular transporters and cuproenzymes, lysyl oxidase among them, the copper-dependent enzyme that cross-links collagen and elastin into mature fibrils. Pickart and Margolina (Int J Mol Sci, 2018) additionally reported broad transcriptional modulation favouring controlled matrix turnover.
TB-500 is based on thymosin beta-4, the principal G-actin sequestering peptide in mammalian cells. It binds actin monomer in a 1:1 complex, holding it unpolymerised as a reservoir that permits rapid localised F-actin polymerisation at a migrating cell's leading edge; the activity localises to the LKKTETQ motif. Malinda et al. (Journal of Investigative Dermatology, 1999) reported accelerated dermal repair in rodent models. Its theme is intracellular — cytoskeletal remodelling and cell motility.
BPC-157 is a 15-residue fragment of a protein isolated from human gastric juice, with no identified high-affinity receptor. Hsieh et al. (Journal of Molecular Medicine, 2017) associated its pro-angiogenic activity with VEGFR2 activation and downstream Akt–eNOS signalling, attenuated by VEGFR2 blockade. Its theme is extracellular and vascular.
Matrix maturation, cell migration and perfusion are three separate constraints on tissue repair, and the blend addresses one apiece. Two caveats belong on the record. No controlled study of this three-compound combination has been published; the evidence base is preclinical work on each constituent. And co-formulating a redox-active copper complex with two copper-free peptides in one vial is not a characterised system.
Evidence
What the research shows
Collagen that matures, not just collagen
Copper delivery supports the enzyme that turns new collagen into mature, load-bearing fibre.
Repair covered from two angles
Cell movement and blood supply are handled by different constituents.
Fixed manufacture ratio
Quantities are set at manufacture; the constituents cannot be varied independently from a single vial.
Combination itself is untested
Each of the three has its own research base; the three-way blend does not.
Reconstitution & handling
Reconstitution and handling in the laboratory
These are general handling notes for the lyophilised peptide supplied by Purist Peptides. They describe the preparation of a stock solution for laboratory work. They are not a dosing protocol, and they describe no administration to a person or an animal.
A 3ml vial of bacteriostatic water is included free with every peptide vial you order, so the material can be reconstituted on arrival.
GLOW — GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg — preparing a stock solution
Choice of diluent
Bacteriostatic water (water for injection with 0.9% benzyl alcohol) is the usual diluent where a stock will be drawn from repeatedly, because the preservative permits several septum entries across a working period. Sterile water for injection and sterile 0.9% sodium chloride are both used where a single-use preparation is wanted instead. The diluent volume sets the concentration of the stock, so record it.
Sterile technique
- Allow the sealed vial to reach room temperature before opening the carton — reconstituting a cold lyophilised cake slows dissolution
- Work in a clean area or a laminar flow cabinet, and wipe the rubber septum with 70% isopropyl alcohol, letting it dry fully
- Draw the chosen volume of diluent using a sterile single-use syringe and needle
- Angle the needle so the diluent runs down the inside wall of the vial — do not direct the stream onto the lyophilised cake
- Roll the vial gently between the palms until the cake has dissolved completely. Do not shake and do not vortex: peptides are surface-active, and agitation drives foaming and aggregation
- Let the vial stand for 5 to 10 minutes. A correctly reconstituted solution is clear and free of visible particles
Working out the concentration
Concentration follows from the mass in the vial and the volume of diluent added, nothing else. Adding 3ml of diluent to the 70mg vial gives a stock of approximately 23.3mg/ml total peptide (16.7mg/ml GHK-Cu, 3.3mg/ml TB-500 and 3.3mg/ml BPC-157); adding 2ml gives 35mg/ml total. Label every reconstituted vial with its concentration and the date it was prepared.
Storage and stability
Before reconstitution
The lyophilised powder is the stable form. Sealed vials are best held at −20°C, protected from light and from moisture; the short periods at 2 to 6°C that occur in transit and on arrival are expected and are accounted for in the supply chain. Keep the vial in its carton — light and humid air are the two ordinary causes of loss on storage.
After reconstitution
Hold reconstituted solution at 2 to 6°C and protect it from light. Do not freeze a working stock: freeze-thaw cycling is the main avoidable cause of degradation and of visible precipitate. Where material must be held beyond a short working period, aliquot the stock into sterile low-binding tubes and freeze the aliquots once at −20°C or below, thawing each aliquot only once.
Checks before use
Inspect every vial against a light source. Discard any solution that is hazy, discoloured or contains particles, and any vial whose septum integrity is in doubt. The independent HPLC assay report for the batch supplied is available on request.
A correctly reconstituted GLOW solution is blue to blue-violet from the coordinated copper(II) of GHK-Cu. Loss of colour or a marked colour shift suggests dissociation of the copper complex.
Strictly for laboratory research use. Not for human or veterinary consumption.
Questions
Frequently asked questions
What is in the GLOW blend?
Three peptides in one lyophilised vial: GHK-Cu, TB-500 and BPC-157, totalling 70mg of peptide content. The individual mg split between the three is not stated on the product page and should be confirmed against the batch documentation before it is quoted anywhere.
Is there published research on the blend itself?
No. No controlled study of these three compounds administered together has been published. The evidence base consists of separate preclinical work on each constituent. The combination is a formulation convention grounded in mechanistic non-overlap, not a validated protocol, and should be described that way.
Does the copper in GHK-Cu affect the other two peptides in a shared vial?
This is not characterised in the published literature. Copper(II) is redox-active, and its behaviour alongside two copper-free peptides in one solution has not been studied to our knowledge. The practical implication is conservative handling: protect from light, avoid reducing agents and chelators, and observe the solution's colour.
How does GLOW differ from KLOW?
KLOW contains the same three peptides plus KPV, the C-terminal tripeptide of alpha-MSH, at a higher total peptide content. The addition is an inflammatory-signalling component rather than a fourth repair mechanism of the same type.
How is purity verified?
Every batch is assayed by Bioindustrial Services in Boksburg, an independent biotechnology laboratory, using HPLC. We do not self-certify. The signed certificate of analysis for each batch — lab number, method and assayed result — is published on our quality standards page.
How long does delivery take?
Orders are dispatched from within South Africa with tracking. Timelines by region and courier are set out on our delivery process page.
What is the returns policy?
Unopened vials in original condition may be returned within the stated window; full terms are in our refund policy.
Ready to order GLOW?
Independently assayed to 99%+ purity. Research use only.
Add to cart — R 1,499.00The Purist Research Standard
Precision-engineered peptides designed to maintain structural integrity under rigorous laboratory conditions.
Optimized Logistics & Fulfillment
Our logistics and fulfillment protocols are engineered to prioritize research stability.
≥99% Research-Grade Purity
Every compound is synthesized to exceed a 99% purity threshold.
Third-Party Laboratory Verified
We maintain total transparency through independent COA.
Precision Lyophilization Technology
Our advanced flash-freeze and vacuum-drying process.
Controlled Synthesis Environment
Produced in sterile, ISO-compliant facilities.
Targeted Research Utility
Engineered as reliable biological models.
Recommended Products
Essential Compounds for Precision Research: Top-Tier Peptides Verified for Structural Integrity.
Testimonials
Real feedback from customers who prioritize purity, precision, and uncompromising quality standards.
